Plain-English translation of NCT07616700 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called HSK39297 to see if it is safe and effective for treating IgA nephropathy, a kidney disease where the immune system damages the kidneys and causes protein to leak into urine. The trial will follow people for an extended period to understand how well this medication works and what side effects might occur. Researchers will track kidney function and urine protein levels to measure whether the treatment helps prevent kidney damage from getting worse.
IgA nephropathy is a serious kidney disease that can gradually lead to kidney failure if not controlled. This medication exists because current treatments may not work well enough for everyone, and doctors are looking for new options to better prevent the disease from progressing and protect kidney function long-term.
You likely qualify if…
You likely don't qualify if…
You will take the medication starting at 200 mg once daily. After 8 to 12 weeks, if your urine protein remains elevated and you have not experienced serious side effects, your doctor may increase the dose to 300 mg once daily. Throughout the study, you will have regular visits to check your kidney function and urine protein levels. After the main treatment period ends, you will have a 4-week follow-up period where your doctor will continue to monitor your safety.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
China